Avanos Medical (AVNS) Accounts Payables (2013 - 2026)

Avanos Medical (AVNS) has 14 years of Accounts Payables data on file, last reported at $52.3 million in Q1 2026.

• For the quarter ending Q1 2026, Accounts Payables rose 13.7% year-over-year to $52.3 million; the trailing twelve-month figure through Mar 2026 stood at $52.3 million (up 13.7% YoY), and the FY2025 full-year result was $55.5 million, up 2.21% from the prior year.
• Accounts Payables fell to $52.3 million in Q1 2026, from $55.5 million in the prior quarter.
• In the past five years, Accounts Payables ranged from a high of $67.9 million in Q4 2022 to a low of $46.0 million in Q1 2025.
• A 5-year average of $56.8 million and a median of $55.5 million in 2025 frame the typical range for Accounts Payables.
• Across the five-year window, Accounts Payables grew 20.39% in 2022 and retreated 21.41% in 2024, its largest moves.
• Tracing AVNS's Accounts Payables over 5 years: stood at $67.9 million in 2022, then retreated by 17.08% to $56.3 million in 2023, then declined by 3.55% to $54.3 million in 2024, then increased by 2.21% to $55.5 million in 2025, then slipped by 5.77% to $52.3 million in 2026.
• Business Quant data shows AVNS's Accounts Payables at $52.3 million in Q1 2026, $55.5 million in Q4 2025, and $54.2 million in Q3 2025.